Tags : Tempest

Clinical Trials

Roche Collaborates with Tempest to Evaluate TPST-1120 in a Combination

Shots: The companies collaborated to evaluate TPST-1120 + Tecentriq (atezolizumab) and Avastin (bevacizumab) in P-Ib/II study in ~60 patients with advanced HCC prior not treated with HCC Tempest will retain the global rights to develop & commercialize TPST-1120 while Roche will manage the study operations for a global study TPST-1120 is a first-in-class selective PPAR⍺ […]Read More